{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:17:10Z","timestamp":1792898230859,"version":"4.5.0"},"reference-count":163,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Reg Anesth Pain Med"],"accepted":{"date-parts":[[2021,7,20]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The past two decades have witnessed an epidemic of opioid use disorder (OUD) in the USA, resulting in catastrophic loss of life secondary to opioid overdoses. Medication treatment of opioid use disorder (MOUD) is effective, yet barriers to care continue to result in a large proportion of untreated individuals. Optimal analgesia can be obtained in patients with MOUD within the perioperative period. Anesthesiologists and pain physicians can recommend and consider initiating MOUD in patients with suspected OUD at the point of care; this can serve as a bridge to comprehensive treatment and ultimately save lives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Board of Directors of the American Society of Regional Anesthesia and Pain Medicine, American Society of Anesthesiologists, American Academy of Pain Medicine, American Society of Addiction Medicine and American Society of Health System Pharmacists approved the creation of a Multisociety Working Group on Opioid Use Disorder, representing the fields of pain medicine, addiction, and pharmacy health sciences. An extensive literature search was performed by members of the working group. Multiple study types were included and reviewed for quality. A modified Delphi process was used to assess the literature and expert opinion for each topic, with 100% consensus being achieved on the statements and each recommendation. The consensus statements were then graded by the committee members using the United States Preventive Services Task Force grading of evidence guidelines. In addition to the consensus recommendations, a narrative overview of buprenorphine, including pharmacology and legal statutes, was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two core topics were identified for the development of recommendations with &gt;75% consensus as the goal for consensus; however, the working group achieved 100% consensus on both topics. Specific topics included (1) providing recommendations to aid physicians in the management of patients receiving buprenorphine for MOUD in the perioperative setting and (2) providing recommendations to aid physicians in the initiation of buprenorphine in patients with suspected OUD in the perioperative setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To decrease the risk of OUD recurrence, buprenorphine should not be routinely discontinued in the perioperative setting. Buprenorphine can be initiated in untreated patients with OUD and acute pain in the perioperative setting to decrease the risk of opioid recurrence and death from overdose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rapm-2021-103007","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T12:25:43Z","timestamp":1628771143000},"page":"840-859","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":139,"title":["Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel"],"prefix":"10.1136","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0407-806X","authenticated-orcid":false,"given":"Lynn","family":"Kohan","sequence":"first","affiliation":[{"name":"Division of Pain Medicine\/Department of Anesthesia, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7081-1154","authenticated-orcid":false,"given":"Sudheer","family":"Potru","sequence":"additional","affiliation":[{"name":"Atlanta VA Medical Center, Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-2797","authenticated-orcid":false,"given":"Antje M","family":"Barreveld","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Tufts University School of Medicine, Newton-Wellesley Hospital, Boston and Newton, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sprintz","sequence":"additional","affiliation":[{"name":"Division of Geriatrics and Palliative Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olabisi","family":"Lane","sequence":"additional","affiliation":[{"name":"Division of Pain Medicine, Department of Anestheisology, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Aryal","sequence":"additional","affiliation":[{"name":"Cedar Recovery and Deparment of Anesthesiology and Pain Medicine, VA Tennessee Valley Healthcare System Nashville Campus, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent","family":"Emerick","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dopp","sequence":"additional","affiliation":[{"name":"American Society Health System Pharmacists, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Chhay","sequence":"additional","affiliation":[{"name":"American Society Health System Pharmacists, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0260-4396","authenticated-orcid":false,"given":"Eugene","family":"Viscusi","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2026102306300716000_46.10.840.1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm655051e1"},{"key":"2026102306300716000_46.10.840.2","unstructured":"Substance Abuse and Mental Health Services Administration . Key substance use and mental health indicators in the United States: results from the 2017 national survey on drug use and health. Available: https:\/\/www.samhsa.gov\/data\/report\/2017-nsduh-annual-national-report [Accessed 21 Mar 2021]."},{"key":"2026102306300716000_46.10.840.3","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.694598"},{"key":"2026102306300716000_46.10.840.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"2026102306300716000_46.10.840.5","first-page":"S243","article-title":"The economic burden of the opioid epidemic on states: the case of Medicaid","volume":"25","author":"Leslie","year":"2019","journal-title":"Am J Manag Care"},{"key":"2026102306300716000_46.10.840.6","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2111"},{"key":"2026102306300716000_46.10.840.7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/M20-1212","article-title":"Collision of the COVID-19 and addiction epidemics","volume":"173","author":"Volkow","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026102306300716000_46.10.840.8","unstructured":"US Centers for Disease Control and Prevention . Overdose deaths accelerating during COVID-19, 2020. Available: https:\/\/www.cdc.gov\/media\/releases\/2020\/p1218-overdose-deaths-covid-19.html [Accessed 10 Mar 2021]."},{"key":"2026102306300716000_46.10.840.9","unstructured":"American Society of Addiction Medicine . Definition of addiction. Available: https:\/\/www.asam.org\/quality-practice\/definition-of-addiction [Accessed 21 Sep 2020]."},{"key":"2026102306300716000_46.10.840.10","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association . Substance-Related and Addictive Disorders. In: Diagnostic and statistical manual of mental disorders. 5 edn, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2026102306300716000_46.10.840.11","unstructured":"American Society of Addiction Medicine . Patient resources. Available: https:\/\/www.asam.org\/Quality-Science\/resource-links\/patient-resources [Accessed 5 Feb 2020]."},{"key":"2026102306300716000_46.10.840.12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra1508490","article-title":"Relationship between nonmedical prescription-opioid use and heroin use","volume":"374","author":"Compton","year":"2016","journal-title":"N Engl J Med Overseas Ed"},{"key":"2026102306300716000_46.10.840.13","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2017.0504","article-title":"New persistent opioid use after minor and major surgical procedures in US adults","volume":"152","author":"Brummett","year":"2017","journal-title":"JAMA Surg"},{"key":"2026102306300716000_46.10.840.14","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2020-101582"},{"key":"2026102306300716000_46.10.840.15","doi-asserted-by":"crossref","unstructured":"Lee JD , Novo P . Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomized controlled trial. Lancet 2018.","DOI":"10.1016\/S0140-6736(17)32812-X"},{"key":"2026102306300716000_46.10.840.16","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.91934"},{"key":"2026102306300716000_46.10.840.17","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102306300716000_46.10.840.18","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"2026102306300716000_46.10.840.19","first-page":"29","article-title":"Buprenorphine: a (relatively) new treatment for opioid dependence","volume":"2","author":"Welsh","year":"2005","journal-title":"Psychiatry"},{"key":"2026102306300716000_46.10.840.20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"key":"2026102306300716000_46.10.840.21","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-9-200805060-00006"},{"key":"2026102306300716000_46.10.840.22","unstructured":"DHHS . SAMHSA Medications for Opioid Use Disorder - Full Document. Treatment Improvement Protocol (TIP) Series 63. Publication No. (SMA) PEP20-02-01-006, 2020."},{"key":"2026102306300716000_46.10.840.23","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.71"},{"key":"2026102306300716000_46.10.840.24","unstructured":"AHFS\u00ae DI Essentials\u2122 . American Society of Health-System Pharmacists\u00ae, 4500 East-West highway, suite 900, Bethesda, MD 20814, 2004."},{"key":"2026102306300716000_46.10.840.25","unstructured":"U.S. Preventive Services Task Force . Grade definitions. Available: https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/grade-definitions [Accessed 5 Apr 2021]."},{"key":"2026102306300716000_46.10.840.26","first-page":"1","article-title":"Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of regional anesthesia and pain medicine, the American Academy of pain medicine, and the American Society of Anesthesiologists","volume":"386","author":"Cohen","year":"2018","journal-title":"Reg Anesth Pain Med"},{"key":"2026102306300716000_46.10.840.27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.36076\/ppj\/447","article-title":"Effectiveness of thermal annular procedures in treating discogenic low back pain","volume":"20","author":"Helm Ii","year":"2017","journal-title":"Pain Physician"},{"key":"2026102306300716000_46.10.840.28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/ner.12579","article-title":"The Polyanalgesic consensus conference (PacC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks","volume":"20","author":"Deer","year":"2017","journal-title":"Neuromodulation"},{"key":"2026102306300716000_46.10.840.29","doi-asserted-by":"crossref","DOI":"10.1097\/PR9.0000000000000687","article-title":"Unique aspects of clinical trials of invasive therapies for chronic pain: an ACTTION evidence-based review","volume":"4","author":"Cohen","year":"2019","journal-title":"Pain Rep"},{"key":"2026102306300716000_46.10.840.30","unstructured":"National Academies of Sciences, Engineering, and Medicine . Medications for opioid use disorder save lives. Washington, DC: The National Academies Press, 2019."},{"key":"2026102306300716000_46.10.840.31","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.2736"},{"key":"2026102306300716000_46.10.840.32","doi-asserted-by":"crossref","unstructured":"Madras BK , Ahmad NJ , Wen J . The prevention, treatment, and recovery Working group of the action collaborative on countering the U.S. opioid epidemic. NAM perspectives. discussion paper, Washington, DC. Available: https:\/\/doi.org\/10.31478\/202004b","DOI":"10.31478\/202004b"},{"key":"2026102306300716000_46.10.840.33","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/jama.2019.3505","article-title":"Making Amends for the opioid epidemic","volume":"321","author":"Sharfstein","year":"2019","journal-title":"JAMA"},{"key":"2026102306300716000_46.10.840.34","first-page":"21","article-title":"Teaching about substance abuse","volume":"10","author":"Yoast","year":"2008","journal-title":"Virtual Mentor"},{"key":"2026102306300716000_46.10.840.35","doi-asserted-by":"publisher","DOI":"10.1177\/1363461516660884"},{"key":"2026102306300716000_46.10.840.36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MLR.0000000000000918","article-title":"Coverage of medications that treat opioid use disorder and opioids for pain management in marketplace plans, 2017","volume":"56","author":"Huskamp","year":"2018","journal-title":"Med Care"},{"key":"2026102306300716000_46.10.840.37","unstructured":"US Department of Health and Human Services . Announcement of practice guidelines for the administration of buprenorphine for treating opioid use disorder. Available: https:\/\/www.hhs.gov\/sites\/default\/files\/mat-physician-practice-guidelines.pdf [Accessed 8 Feb 2021]."},{"key":"2026102306300716000_46.10.840.38","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.addbeh.2006.01.003","article-title":"Does this patient really want treatment? factors associated with baseline and evolving readiness for change among hospitalized substance using adults interested in treatment","volume":"31","author":"Pollini","year":"2006","journal-title":"Addict Behav"},{"key":"2026102306300716000_46.10.840.39","unstructured":"Coffa D , Harter K , Smith B . Acute pain and perioperative management in opioid use disorder: pain control in patients on buprenorphine, methadone, or naltrexone. SHOUT guidelines. California health care Foundation. Available: https:\/\/drive.google.com\/drive\/folders\/1TYvygcY2FcQjvdgEjfvo4JtEvkkOxBe4 [Accessed 20 Sep 2020]."},{"key":"2026102306300716000_46.10.840.40","doi-asserted-by":"publisher","DOI":"10.1111\/add.13193"},{"key":"2026102306300716000_46.10.840.41","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","article-title":"Societal costs of prescription opioid abuse, dependence, and misuse in the United States","volume":"12","author":"Birnbaum","year":"2011","journal-title":"Pain Med"},{"key":"2026102306300716000_46.10.840.42","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2005.11.6.469"},{"key":"2026102306300716000_46.10.840.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141073","article-title":"Drugs-related death soon after hospital-discharge among drug treatment clients in Scotland: record linkage, validation, and investigation of risk-factors","volume":"10","author":"White","year":"2015","journal-title":"PLoS One"},{"key":"2026102306300716000_46.10.840.44","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"2026102306300716000_46.10.840.45","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMp2101298","article-title":"The Number Needed to Prescribe - What Would It Take to Expand Access to Buprenorphine?","volume":"384","author":"Poorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026102306300716000_46.10.840.46","doi-asserted-by":"publisher","DOI":"10.1111\/add.12863"},{"key":"2026102306300716000_46.10.840.47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0963689718811060","article-title":"Historical review: opiate addiction and opioid receptors","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Transplant"},{"key":"2026102306300716000_46.10.840.48","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"2026102306300716000_46.10.840.49","unstructured":"Methadone . DailyMed. US national library of medicine, 2020. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/search.cfm?labeltype=all&query=methadone [Accessed 8 Feb 2021]."},{"key":"2026102306300716000_46.10.840.50","unstructured":"Buprenorphine . DailyMed. US national library of medicine, 2020. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/search.cfm?labeltype=all&query=buprenorphine [Accessed 8 Feb 2021]."},{"key":"2026102306300716000_46.10.840.51","unstructured":"Naltrexone . DailyMed. US national library of medicine, 2020. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/search.cfm?labeltype=all&query=naltrexone [Accessed 8 Feb 2021]."},{"key":"2026102306300716000_46.10.840.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2004.05.002"},{"key":"2026102306300716000_46.10.840.53","article-title":"Buprenorphine for managing opioid withdrawal","volume":"2","author":"Gowing","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026102306300716000_46.10.840.54","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00057-7"},{"key":"2026102306300716000_46.10.840.55","unstructured":"Suboxone . Buprenorphine hydrochloride and naloxone hydrochloride dehydrate) sublingual film. prescribing information. Individior, Inc, 2019. Available: https:\/\/www.suboxone.com\/pdfs\/prescribing-information.pdf [Accessed 7 Jul 2021]."},{"key":"2026102306300716000_46.10.840.56","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3723-08.2009"},{"key":"2026102306300716000_46.10.840.57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06352.x"},{"key":"2026102306300716000_46.10.840.58","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12196"},{"key":"2026102306300716000_46.10.840.59","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2147\/JPR.S160255","article-title":"Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials","volume":"11","author":"Meske","year":"2018","journal-title":"J Pain Res"},{"key":"2026102306300716000_46.10.840.60","doi-asserted-by":"publisher","DOI":"10.1186\/1865-1380-7-1"},{"key":"2026102306300716000_46.10.840.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.06.030"},{"key":"2026102306300716000_46.10.840.62","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2147\/TCRM.S141332","article-title":"The challenge of perioperative pain management in opioid-tolerant patients","volume":"13","author":"Coluzzi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"2026102306300716000_46.10.840.63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/pm\/pny019","article-title":"Patients maintained on buprenorphine for opioid use disorder should continue buprenorphine through the perioperative period","volume":"20","author":"Lembke","year":"2019","journal-title":"Pain Med"},{"key":"2026102306300716000_46.10.840.64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11673-017-9784-y","article-title":"Stigma and Self-Stigma in addiction","volume":"14","author":"Matthews","year":"2017","journal-title":"J Bioeth Inq"},{"key":"2026102306300716000_46.10.840.65","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1213\/ANE.0000000000003477","article-title":"Opioid use disorders: perioperative management of a special population","volume":"127","author":"Ward","year":"2018","journal-title":"Anesth Analg"},{"key":"2026102306300716000_46.10.840.66","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31823c1067"},{"key":"2026102306300716000_46.10.840.67","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.140"},{"key":"2026102306300716000_46.10.840.68","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4603(82)90005-3"},{"key":"2026102306300716000_46.10.840.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2006.08.002"},{"key":"2026102306300716000_46.10.840.70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1511480"},{"key":"2026102306300716000_46.10.840.71","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugalcdep.2016.06.024","article-title":"Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy","volume":"166","author":"Tsui","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"2026102306300716000_46.10.840.72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.01759.x"},{"key":"2026102306300716000_46.10.840.73","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000001633"},{"key":"2026102306300716000_46.10.840.74","unstructured":"Center for Substance Abuse Treatment Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction . Treatment improvement protocol (tip) series 40. DHHS publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health, 2004."},{"key":"2026102306300716000_46.10.840.75","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/0310057X1304100212","article-title":"Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy","volume":"41","author":"Macintyre","year":"2013","journal-title":"Anaesth Intensive Care"},{"key":"2026102306300716000_46.10.840.76","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181be0804"},{"key":"2026102306300716000_46.10.840.77","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/15360288.2016.1231734","article-title":"Continuous perioperative sublingual buprenorphine","volume":"30","author":"Silva","year":"2016","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2026102306300716000_46.10.840.78","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/ADM.0000000000000339","article-title":"Comparison of post-cesarean section opioid analgesic requirements in women with opioid use disorder treated with methadone or buprenorphine","volume":"11","author":"Vilkins","year":"2017","journal-title":"J Addict Med"},{"key":"2026102306300716000_46.10.840.79","doi-asserted-by":"crossref","first-page":"679","DOI":"10.36076\/ppj.2009\/12\/679","article-title":"Opioid induced hyperalgesia: clinical implications for the pain practitioner","volume":"12","author":"Silverman","year":"2009","journal-title":"Pain Physician"},{"key":"2026102306300716000_46.10.840.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.01.013"},{"key":"2026102306300716000_46.10.840.81","unstructured":"American Society of Addiction Medicine . National practice guideline for the treatment of opioid use disorder. Available: https:\/\/www.asam.org\/docs\/default-source\/quality-science\/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2 [Accessed 22 Sep 2020]."},{"key":"2026102306300716000_46.10.840.82","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"2026102306300716000_46.10.840.83","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12630-018-1255-3","article-title":"The perioperative patient on buprenorphine: a systematic review of perioperative management strategies and patient outcomes. Le patient en p\u00e9riode p\u00e9riop\u00e9ratoire sous bupr\u00e9norphine: revue syst\u00e9matique des strat\u00e9gies de gestion p\u00e9riop\u00e9ratoire et de l\u2019\u00e9volution des patients","volume":"66","author":"Goel","year":"2019","journal-title":"Can J Anaesth"},{"key":"2026102306300716000_46.10.840.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.10.007"},{"key":"2026102306300716000_46.10.840.85","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300251"},{"key":"2026102306300716000_46.10.840.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.07.035"},{"key":"2026102306300716000_46.10.840.87","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00110-X"},{"key":"2026102306300716000_46.10.840.88","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/pm\/pny217","article-title":"Perioperative management of buprenorphine: solving the conundrum","volume":"20","author":"Quaye","year":"2019","journal-title":"Pain Med"},{"key":"2026102306300716000_46.10.840.89","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0023-6"},{"key":"2026102306300716000_46.10.840.90","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-001-0975-0"},{"key":"2026102306300716000_46.10.840.91","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/j.bja.2019.03.044","article-title":"Perioperative pain and addiction interdisciplinary network (pain) clinical practice Advisory for perioperative management of buprenorphine: results of a modified Delphi process","volume":"123","author":"Goel","year":"2019","journal-title":"Br J Anaesth"},{"key":"2026102306300716000_46.10.840.92","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.164.6.979"},{"key":"2026102306300716000_46.10.840.93","article-title":"Perioperative pain management for patients on chronic buprenorphine: a case report","volume":"3","author":"Chern","year":"2013","journal-title":"J Anesth Clin Res"},{"key":"2026102306300716000_46.10.840.94","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12630-014-0193-y","article-title":"Perioperative management of a patient undergoing Clagett window closure stabilized on Suboxone\u00ae for chronic pain: a case report","volume":"61","author":"Huang","year":"2014","journal-title":"Can J Anaesth"},{"key":"2026102306300716000_46.10.840.95","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0b013e32835b822b"},{"key":"2026102306300716000_46.10.840.96","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2020-101324"},{"key":"2026102306300716000_46.10.840.97","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/pm\/pnz260","article-title":"A multidisciplinary patient-specific opioid prescribing and tapering protocol is associated with a decrease in total opioid dose prescribed for six weeks after total hip arthroplasty","volume":"21","author":"Tamboli","year":"2020","journal-title":"Pain Med"},{"key":"2026102306300716000_46.10.840.98","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/jhm.358","article-title":"Tobacco, alcohol, and drug use and willingness to change","volume":"3","author":"Katz","year":"2008","journal-title":"J Hosp Med"},{"key":"2026102306300716000_46.10.840.99","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4187\/respcare.08531217","article-title":"Treating tobacco use and dependence: 2008 update U.S. public health service clinical practice guideline executive summary","volume":"53","year":"2008","journal-title":"Respir Care"},{"key":"2026102306300716000_46.10.840.100","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-9-201211060-00544"},{"key":"2026102306300716000_46.10.840.101","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3474"},{"key":"2026102306300716000_46.10.840.102","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2026102306300716000_46.10.840.103","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.arth.2016.01.032","article-title":"Total joint arthroplasty in patients taking methadone or buprenorphine\/naloxone preoperatively for prior heroin addiction: a prospective matched cohort study","volume":"31","author":"Hansen","year":"2016","journal-title":"J Arthroplasty"},{"key":"2026102306300716000_46.10.840.104","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-014-2968-9"},{"key":"2026102306300716000_46.10.840.105","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) . Drug abuse warning network, 2011: national estimates of drug-related emergency department visits. Available: http:\/\/www.samhsa.gov\/data\/2k13\/DAWN2k11ED\/DAWN2k11ED.htm#5.1 [Accessed 21 May 2020]."},{"key":"2026102306300716000_46.10.840.106","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/papr.12996","article-title":"An anesthesiologist\u2010led inpatient buprenorphine initiative","volume":"21","author":"Patel","year":"2021","journal-title":"Pain Pract"},{"key":"2026102306300716000_46.10.840.107","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(02)00325-3"},{"key":"2026102306300716000_46.10.840.108","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.11.008"},{"key":"2026102306300716000_46.10.840.109","first-page":"1","article-title":"One year mortality of patients treated with naloxone for opioid overdose by emergency medical services","author":"Weiner","year":"2020","journal-title":"Subst Abus"},{"key":"2026102306300716000_46.10.840.110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.drugalcdep.2018.04.021","article-title":"Substance use and homelessness among emergency department patients","volume":"188","author":"Doran","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2026102306300716000_46.10.840.111","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) . Special circumstances for providing buprenorphine, 2016. Available: https:\/\/www.samhsa.gov\/medication-assisted-treatment\/legislation-regulations-guidelines\/special-circumstances-providing-buprenorphine [Accessed 21 May 2020]."},{"key":"2026102306300716000_46.10.840.112","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5475"},{"key":"2026102306300716000_46.10.840.113","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.annemergmed.2018.01.052","article-title":"Opportunities for prevention and intervention of opioid overdose in the emergency department","volume":"71","author":"Houry","year":"2018","journal-title":"Ann Emerg Med"},{"key":"2026102306300716000_46.10.840.114","unstructured":"American College of Emergency Physicians . State legislation requiring emergency medication assisted therapy for opioid use disorder. Available: https:\/\/www.acep.org\/how-we-serve\/sections\/toxicology\/news\/september-2018\/state-legislation-requiring-emergency-medication-assisted-therapy-for-opioid-use-disorder\/ [Accessed 5 Apr 2021]."},{"key":"2026102306300716000_46.10.840.115","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ajem.2019.158373","article-title":"Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program","volume":"38","author":"Kaucher","year":"2020","journal-title":"Am J Emerg Med"},{"key":"2026102306300716000_46.10.840.116","unstructured":"Vestal C . Few doctors are willing, able to prescribe powerful anti-addiction drugs, 2016. Available: http:\/\/www.pewtrusts.org\/en\/research-and-analysis\/blogs\/stateline\/2016\/01\/15\/few-doctors-are-willing-able-to-prescribe-powerful-anti-addiction-drugs [Accessed 5 Apr 2021]."},{"key":"2026102306300716000_46.10.840.117","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.74018","article-title":"Buprenorphine\u2013naloxone \u201cmicrodosing\u201d: an alternative induction approach for the treatment of opioid use disorder in the wake of North America\u2019s increasingly potent illicit drug market","volume":"192","author":"Randhawa","year":"2020","journal-title":"Can Med Assoc J"},{"key":"2026102306300716000_46.10.840.118","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-0030-1261914","article-title":"Einleitung einer Substitutionsbehandlung mit Buprenorphin unter vor\u00fcbergehender \u00dcberlappung mit Heroinkonsum: ein neuer Ansatz (\u201eBerner Methode\u201d)","volume":"11","author":"H\u00e4mmig","year":"2010","journal-title":"Suchttherapie"},{"key":"2026102306300716000_46.10.840.119","article-title":"Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method","volume":"7","author":"H\u00e4mmig","year":"2016","journal-title":"Subst Abuse Rehabil"},{"key":"2026102306300716000_46.10.840.120","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ajad.12869","article-title":"Rapid micro-induction of buprenorphine\/naloxone for opioid use disorder in an inpatient setting: a case series","volume":"28","author":"Klaire","year":"2019","journal-title":"Am J Addict"},{"key":"2026102306300716000_46.10.840.121","doi-asserted-by":"crossref","unstructured":"Moe J , Badke K , Pratt M . Microdosing and standard-dosing take-home buprenorphine from the emergency department: a feasibility study. J Am Coll Emerg Physicians Open 2020.","DOI":"10.1002\/emp2.12289"},{"key":"2026102306300716000_46.10.840.122","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.annemergmed.2018.11.032","article-title":"Managing opioid withdrawal in the emergency department with buprenorphine","volume":"73","author":"Herring","year":"2019","journal-title":"Ann Emerg Med"},{"key":"2026102306300716000_46.10.840.123","unstructured":"ToolkitsE-QO. Available: https:\/\/www.acep.org\/administration\/quality\/equal\/emergency-quality-network-e-qual\/e-qual-opioid-initiative\/e-qual-opioid-toolkit\/ [Accessed 13 Mar 2021]."},{"key":"2026102306300716000_46.10.840.124","unstructured":"National Institute of Drug Abuse . Initiating buprenorphine treatment in the emergency department. Available: https:\/\/www.drugabuse.gov\/nidamed-medical-health-professionals\/discipline-specific-resources\/emergency-physicians-first-responders\/initiating-buprenorphine-treatment-in-emergency-department [Accessed 5 Apr 2021]."},{"key":"2026102306300716000_46.10.840.125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116716","article-title":"Buprenorphine initiation to treat opioid use disorder in emergency rooms","volume":"411","author":"Jaeger","year":"2020","journal-title":"J Neurol Sci"},{"key":"2026102306300716000_46.10.840.126","unstructured":"CA bridge. Available: https:\/\/cabridge.org\/resource\/buprenorphine-bup-hospital-quick-start\/ Buprenorphine Hospital Quick Start [Accessed 5 Apr 2021]."},{"key":"2026102306300716000_46.10.840.127","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.678938"},{"key":"2026102306300716000_46.10.840.128","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S0196-0644(20)30626-0","article-title":"Clinical policy: critical issues related to opioids in adult patients presenting to the emergency department","volume":"76","author":"Hatten","year":"2020","journal-title":"Ann Emerg Med"},{"key":"2026102306300716000_46.10.840.129","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000166"},{"key":"2026102306300716000_46.10.840.130","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","article-title":"Updated clinical pharmacokinetics and pharmacodynamics of oxycodone","volume":"58","author":"Kinnunen","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026102306300716000_46.10.840.131","doi-asserted-by":"crossref","first-page":"330???336","DOI":"10.1213\/00000539-199103000-00009","article-title":"Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects","volume":"72","author":"Hill","year":"1991","journal-title":"Anesth Analg"},{"key":"2026102306300716000_46.10.840.132","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jsat.2016.06.003","article-title":"Buprenorphine initiation and linkage to outpatient buprenorphine do not reduce frequency of injection opiate use following hospitalization","volume":"68","author":"Cushman","year":"2016","journal-title":"J Subst Abuse Treat"},{"key":"2026102306300716000_46.10.840.133","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ajad.12161","article-title":"Initiating buprenorphine treatment for hospitalized patients with opioid dependence: a case series","volume":"24","author":"Suzuki","year":"2015","journal-title":"Am J Addict"},{"key":"2026102306300716000_46.10.840.134","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annemergmed.2018.04.007","article-title":"Identification, management, and transition of care for patients with opioid use disorder in the emergency department","volume":"72","author":"Duber","year":"2018","journal-title":"Ann Emerg Med"},{"key":"2026102306300716000_46.10.840.135","unstructured":"Substance abuse and mental health services administration (SAMHSA) buprenorphine practitioner locator. Available: https:\/\/www.samhsa.gov\/medication-assisted-treatment\/practitioner-program-data\/treatment-practitioner-locator [Accessed 6 Apr 2021]."},{"key":"2026102306300716000_46.10.840.136","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsat.2019.05.006","article-title":"A scalable, automated warm handoff from the emergency department to community sites offering continued medication for opioid use disorder: lessons learned from the embed trial stakeholders","volume":"102","author":"Ahmed","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"2026102306300716000_46.10.840.137","unstructured":"National alliance of Advocates for buprenorphine treatment treatment match. Available: https:\/\/www.treatmentmatch.org\/ [Accessed 5 Apr 2021]."},{"key":"2026102306300716000_46.10.840.138","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ajem.2019.12.038","article-title":"A novel social work approach to emergency department buprenorphine induction and warm hand-off to community providers","volume":"38","author":"Kelly","year":"2020","journal-title":"Am J Emerg Med"},{"key":"2026102306300716000_46.10.840.139","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5811\/westjem.2020.7.46079","article-title":"Beyond buprenorphine: models of follow-up care for opioid use disorder in the Emergeny department","volume":"21","author":"Martin","year":"2020","journal-title":"West J Emerg Med"},{"key":"2026102306300716000_46.10.840.140","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01154.x"},{"key":"2026102306300716000_46.10.840.141","unstructured":"Title 21 code of federal regulations. \u00a71306.07. administering or dispensing of narcotic drugs, 2020. Available: https:\/\/www.govinfo.gov\/app\/details\/CFR-2020-title21-vol9\/CFR-2020-title21-vol9-sec1306-07"},{"key":"2026102306300716000_46.10.840.142","unstructured":"Cabridge.org . Best practices: inpatient and order set guideline. Available: https:\/\/static1.squarespace.com\/static\/5c412ab755b02cec3b4ed998\/t\/5dc2504c449ab61155c0b1d1\/1573015629142\/CA+Bridge+-+Best+Practices+-+Inpatient+and+order+sets+-+NOV+2019.pdf [Accessed 3 Jun 2021]."},{"key":"2026102306300716000_46.10.840.143","unstructured":"Federal Registrar . Federal guidelines on the for the administration of buprenorphine for treating OUD. Available: https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder [Accessed 28 Apr 2021]."},{"key":"2026102306300716000_46.10.840.144","unstructured":"Centers for Disease Control and Prevention . Emergency preparedness and response. Available: https:\/\/emergency.cdc.gov\/han\/2020\/han00438.asp [Accessed 28 Apr 2021]."},{"key":"2026102306300716000_46.10.840.145","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) . Medication assisted treatment. buprenorphine, 2016. Available: https:\/\/www.samhsa.gov\/medication-assisted-treatment\/medications-counseling-related-conditions\/buprenorphine [Accessed 5 Apr 2021]."},{"key":"2026102306300716000_46.10.840.146","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1978.01770280111012"},{"key":"2026102306300716000_46.10.840.147","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13181-020-00795-3","article-title":"Opioid overdose deaths with buprenorphine detected in postmortem toxicology: a retrospective analysis","volume":"17","author":"Wightman","year":"2021","journal-title":"J Med Toxicol"},{"key":"2026102306300716000_46.10.840.148","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e3181a193f5"},{"key":"2026102306300716000_46.10.840.149","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5055\/jom.2009.0018","article-title":"Dexmedetomidine as a novel therapeutic for postoperative pain in a patient treated with buprenorphine","volume":"5","author":"Brummett","year":"2009","journal-title":"J Opioid Manag"},{"key":"2026102306300716000_46.10.840.150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/ADM.0b013e3182486e44","article-title":"Double successful buprenorphine\/naloxone induction to facilitate cardiac transplantation in an iatrogenically opiate-dependent patient","volume":"6","author":"Rodgman","year":"2012","journal-title":"J Addict Med"},{"key":"2026102306300716000_46.10.840.151","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/pme.12135","article-title":"Acute pain control challenges with buprenorphine\/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review","volume":"14","author":"McCormick","year":"2013","journal-title":"Pain Med"},{"key":"2026102306300716000_46.10.840.152","doi-asserted-by":"crossref","first-page":"657e","DOI":"10.1097\/PRS.0b013e31828277bd","article-title":"The clinical conundrum of perioperative pain management in patients with opioid dependence: lessons from two cases","volume":"131","author":"Israel","year":"2013","journal-title":"Plast Reconstr Surg"},{"key":"2026102306300716000_46.10.840.153","doi-asserted-by":"crossref","first-page":"E261","DOI":"10.36076\/ppj\/2015.18.E261","article-title":"Effect of buprenorphine on total intravenous anesthetic requirements during spine surgery","volume":"18","author":"Khelemsky","year":"2015","journal-title":"Pain Physician"},{"key":"2026102306300716000_46.10.840.154","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/10550490600626721","article-title":"Post-cesarean pain management of patients maintained on methadone or buprenorphine","volume":"15","author":"Jones","year":"2006","journal-title":"Am J Addict"},{"key":"2026102306300716000_46.10.840.155","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ejpain.2011.08.008","article-title":"Peripartum pain management in opioid dependent women","volume":"16","author":"H\u00f6flich","year":"2012","journal-title":"Eur J Pain"},{"key":"2026102306300716000_46.10.840.156","doi-asserted-by":"crossref","first-page":"E163","DOI":"10.36076\/ppj.2020\/23\/E163","article-title":"Continuation of buprenorphine to facilitate postoperative pain management for patients on buprenorphine opioid agonist therapy","volume":"23","author":"Mehta","year":"2020","journal-title":"Pain Physician"},{"key":"2026102306300716000_46.10.840.157","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-2-200601170-00010"},{"key":"2026102306300716000_46.10.840.158","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/jpm.2012.9591","article-title":"Treatment of pain in patients taking buprenorphine for opioid addiction #221","volume":"15","author":"Childers","year":"2012","journal-title":"J Palliat Med"},{"key":"2026102306300716000_46.10.840.159","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/ACO.0000000000000052","article-title":"The perioperative management of patients maintained on medications used to manage opioid addiction","volume":"27","author":"Bryson","year":"2014","journal-title":"Curr Opin Anaesthesiol"},{"key":"2026102306300716000_46.10.840.160","doi-asserted-by":"crossref","DOI":"10.1007\/s11916-016-0549-9","article-title":"New pain management options for the surgical patient on methadone and buprenorphine","volume":"20","author":"Sen","year":"2016","journal-title":"Curr Pain Headache Rep"},{"key":"2026102306300716000_46.10.840.161","first-page":"E1","article-title":"Buprenorphine formulations: clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures","volume":"21","author":"Jonan","year":"2018","journal-title":"Pain Physician"},{"key":"2026102306300716000_46.10.840.162","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.anclin.2018.04.002","article-title":"Perioperative considerations for the patient with opioid use disorder on buprenorphine, methadone, or naltrexone maintenance therapy","volume":"36","author":"Harrison","year":"2018","journal-title":"Anesthesiol Clin"},{"key":"2026102306300716000_46.10.840.163","unstructured":"Berry P , Besio S , Brooklyn J . Vermont practice guidelines 2015; Vermont department of health; division of alcohol and drug abuse programs. Available: http:\/\/contentmanager.med.uvm.edu\/docs\/default-source\/vchip-documents\/vchip_2buprenorphine_guidelines.pdf?sfvrsn=2 [Accessed 14 Mar 2021]."}],"container-title":["Regional Anesthesia &amp; Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rapm-2021-103007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:31:30Z","timestamp":1792762290000},"score":1,"resource":{"primary":{"URL":"https:\/\/rapm.bmj.com\/lookup\/doi\/10.1136\/rapm-2021-103007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":163,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,9,20]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/rapm-2021-103007"],"URL":"https:\/\/doi.org\/10.1136\/rapm-2021-103007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740634991.793589258","asserted-by":"object"}]},"ISSN":["1098-7339","1532-8651"],"issn-type":[{"value":"1098-7339","type":"print"},{"value":"1532-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]}}}